Biovica International
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Announces Launch of Secondary Public Offering13.5.2025 16:26:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today the launch of a secondary underwritten public offering of 9,000,000 shares of its common stock by certain of its stockholders. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Such selling stockholders will receive all of the proceeds from this offering. Loar is not selling any shares of common stock in this offering and will not receive any proceeds from this offering. Jefferies and Morgan Stanley are acting as lead book runners for the proposed offering. Blackstone is acting as co-manager. An automatic shelf registration statement (including a base prospectus) relating to this offering of common stock was filed by Loar with the Securities and Exchange Commission (the "SEC") on May 1, 2025 and became effec
Detego Global Announces Sponsorship of British Police Rugby Team for 2025 Centenary Tour of South Africa13.5.2025 12:30:00 CEST | Press release
HORSHAM, UNITED KINGDOM / ACCESS Newswire / May 13, 2025 / Following the resounding success of their sponsorship of the England Police Rugby Team's 2024 South African tour, Detego Global, the leading provider of cutting-edge digital forensics and investigative technology, is proud to announce its sponsorship of the British Police Rugby Team's 2025 centenary tour of South Africa, bringing together players from all four nations of England, Ireland, Scotland, and Wales. This new partnership strengthens a shared commitment to community engagement and global cooperation whilst marking an important occasion - the beginning of the British Police Rugby Team's centenary celebrations. Founded in 1925, the British Police Rugby Team has upheld a proud tradition of sporting excellence and service for a century. The 2025 tour of South Africa launches a year of commemorative events and fixtures, starting with two major matches, including one at the world-famous Hollywoodbets Kings Park Stadium in Dur
Loar Holdings Inc. Reports Q1 2025 Record Results and Upward Revision to 2025 Outlook13.5.2025 08:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 13, 2025 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2025. First Quarter 2025 Net sales of $114.7 million, up 24.8% compared to the prior year's quarter. Net income of $15.3 million, up $13.1 million compared to the prior year's quarter. Diluted earnings per share of $0.16. Adjusted EBITDA of $43.1 million, up 30.6% compared to the prior year's quarter. Net income margin for the quarter improved to 13.4% compared to the prior year's quarter net income margin of 2.4%. Adjusted EBITDA Margin for the quarter improved to 37.6% compared to 36.0% for the prior year's quarter. Adjusted Earnings Per Share of $0.20. "We began 2025 with excellent momentum from strong demand across our end-markets," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. "In the quarter, sales to our Original Equipment, Commercial Aftermarket and Defense marke
OMP's Unison Planning Achieves SAP(R) Certified Integration with RISE with SAP S/4HANA(R) Cloud13.5.2025 07:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / May 13, 2025 / OMP, a global leader in supply chain planning solutions, announced today that its Unison PlanningTM platform has achieved SAP® certification as integrated with RISE with SAP S/4HANA® Cloud. Continuing its long history of providing SAP-certified integration, this milestone confirms Unison Planning's full support for S/4HANA environments and its compatibility with RISE with SAP. The integration delivers seamless, near-real-time connectivity between SAP and Unison Planning's advanced supply chain capabilities, reinforcing OMP's role as a trusted partner for navigating complex planning environments. "Achieving this certification highlights our commitment to innovation and enterprise-grade reliability," says Tom Wouters, Chief Product Officer at OMP. "It confirms our ability to support global businesses in their digital transformation journeys, especially those migrating to S/4HANA with RISE with SAP." OMP was recently recognized as a Leader
BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory13.5.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / May 13, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is pleased to announce the integration of its research, development and commercialization activities to the Gen-Plus GmbH & Co. KG (Gen-Plus) Contract Research and Development Organization (CRDO) in Munich, Germany. The move provides BioNxt with enhanced R&D capabilities, collaboration opportunities, and accelerated innovation potential within a major European biotech hub. The Company seeks to leverage the advanced and innovative infrastructure of the Gen-Plus Laboratory and harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom